arrow
H

Hayato Kawachi

Kyoto Prefectural University of Medicine
H指数:16
被引数:1,115

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health care contact days after second-line systemic therapy in patients with advanced non-small cell lung cancer in Japan with or without subsequent systemic therapy

日本接受二线全身治疗后的晚期非小细胞肺癌患者,在有无后续全身治疗情况下的医疗接触天数

2026-10-080
PRE
Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease

基线中性粒细胞与淋巴细胞比率可预测间质性肺病患者开始使用nintedanib后的生存时间

2026-05-190
OAAI
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer

晚期非小细胞肺癌的初始生物标志物检测策略与临床结局

2026-05-150
OAAI
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance

EGFR突变非小细胞肺癌TKI耐药后,癌症恶病质预测免疫治疗联合化疗的获益

2026-05-010
PRE
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组:AWGC与Fearon标准的比较分析

2026-04-120
OAAI
AXL–SHC1 signaling axis mediates adaptive resistance to HER2-targeted tyrosine kinase inhibitors in HER2-aberrant lung and gastric cancers

AXL–SHC1信号轴介导了HER2-aberrant肺癌和胃癌对HER2靶向酪氨酸激酶抑制剂的适应性耐药。

2026-04-020
OAAI
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan

特发性肺间质疾病患者接受尼达尼布治疗后的预后因素:一项在日本进行的多中心回顾性研究

2025-12-270
OAAI
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法:用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌:帕博利珠单抗单药治疗与联合化疗免疫疗法

2025-11-300
PRE
Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study

肺癌免疫预后指数在PD-L1低表达/阴性肿瘤的非小细胞肺癌患者接受化疗免疫治疗中的影响:一项真实世界多中心回顾性研究

2025-11-200
OAAI
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
2025-11-011
PRE
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
2024-12-160
OAAI
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)

局部晚期非小细胞肺癌放化疗和巩固Durvalumab治疗后进展后后续化疗的真实世界结果: 来自CRIMSON研究的探索性分析 (HOPE-005)

2024-11-012
PRE
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响:化疗与化疗免疫治疗的多中心回顾性研究

2024-10-250
OA
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
2024-08-210
PRE
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
2024-07-150
OAAI
AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

AXL信号介导KRAS G12C-mutant肿瘤细胞对KRAS G12C抑制剂的适应性耐药

2024-04-010
OAAI